Compare DDS & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDS | BIO |
|---|---|---|
| Founded | 1938 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | DDS | BIO |
|---|---|---|
| Price | $626.58 | $301.37 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $511.33 | $358.50 |
| AVG Volume (30 Days) | 140.4K | ★ 173.1K |
| Earning Date | 11-13-2025 | 02-12-2026 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 36.93 | N/A |
| Revenue | ★ $6,625,563,000.00 | $2,557,500,000.00 |
| Revenue This Year | $0.60 | $1.77 |
| Revenue Next Year | N/A | $2.30 |
| P/E Ratio | $16.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $282.24 | $211.43 |
| 52 Week High | $741.98 | $373.69 |
| Indicator | DDS | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 41.67 |
| Support Level | $602.75 | $295.01 |
| Resistance Level | $663.58 | $307.07 |
| Average True Range (ATR) | 27.22 | 8.47 |
| MACD | -10.47 | -1.47 |
| Stochastic Oscillator | 17.00 | 20.90 |
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.